Marinus Appoints Scott Braunstein, MD to its Board of Directors
September 05 2018 - 7:30AM
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical
company dedicated to the development of innovative therapeutics to
treat epilepsy and neuropsychiatric disorders, today announced the
appointment of Dr. Scott Braunstein to its Board of Directors.
“We are excited to have Dr. Braunstein join our
Board,” commented Christopher M. Cashman, chief executive officer
of Marinus Pharmaceuticals. “Dr. Braunstein is well-known in the
healthcare industry for his successful track record as an investor
and for providing strategic and organizational expertise in various
operational roles. Drawing on his knowledge of Wall Street and
strategic guidance, Scott will provide fresh insights as Marinus
advances its late-stage portfolio of programs.”
Dr. Braunstein brings over 20 years of knowledge
and experience from diverse biotechnology and pharmaceutical
industry vantage points. Dr. Braunstein is currently an operating
partner at Aisling Capital. He most recently served as chief
operating officer at Pacira Pharmaceuticals, Inc., a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. Prior to Pacira, Scott served as
a healthcare portfolio manager at Everpoint Asset Management and
spent 12 years with J.P. Morgan Asset Management as a healthcare
analyst and managing director in the U.S. Equity team, and as a
portfolio manager in the Global Healthcare team responsible for
managing investments in pharmaceuticals, biotechnology, and medical
devices. Dr. Braunstein is currently on the board of directors at
Esperion Therapeutics and serves as chairman at ArTara
Therapeutics. Scott began his career as a practicing physician at
the Summit Medical Group and as assistant clinical professor at
Albert Einstein College of Medicine and Columbia University Medical
Center. He earned his medical degree from the Albert Einstein
College of Medicine.
“I am happy to join the Marinus Board at a time
when the Company is making great strides in the clinical
development of ganaxolone for postpartum depression and CDKL5
deficiency disorder,” commented Dr. Braunstein. “I look forward to
working with other Board members and management as we continue to
advance ganaxolone into late-stage clinical trials.”
About Marinus
PharmaceuticalsMarinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a positive allosteric modulator of GABAA that acts on
a well-characterized target in the brain known to have
anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone
is being developed in three different dose forms (IV, capsule and
liquid) intended to maximize therapeutic reach to adult and
pediatric patient populations in both acute and chronic care
settings. Marinus has initiated the first ever pivotal study
in children with CDKL5 deficiency disorder, a rare form of
epilepsy, and is currently conducting studies in patients with
postpartum depression and refractory status epilepticus. For more
information visit www.marinuspharma.com. Please follow us on
Twitter: @MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Marinus, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the conduct of future clinical trials, the timing of the
clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, the attainment of clinical trial results that will be
supportive of regulatory approvals, and other matters, including
the development of formulations of ganaxolone, and the availability
or potential availability of alternative products or treatments for
conditions targeted by the Company that could affect the
availability or commercial potential of our drug candidates.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
CONTACT:Lisa M. CaperelliExecutive Director, Investor &
Strategic RelationsMarinus Pharmaceuticals,
Inc.484-801-4674lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Sep 2023 to Sep 2024